Clomiphene: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Clomiphene. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Ovarian enlargement | 13.6% |
| Vasomotor flushes | 10.4% |
| Nausea and vomiting | 2.2% |
| Breast discomfort | 2.1% |
| Visual symptoms | 1.5% |
| Headache | 1.3% |
| Abnormal uterine bleeding | 1.3% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Pa…
Medical disclaimer: Always consult a qualified healthcare professional about any medication.